You Hanxiao, Zhao Jiuliang, Huang Can, Tian Xinping, Li Mengtao, Zeng Xiaofeng
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Front Med (Lausanne). 2021 Feb 4;8:630660. doi: 10.3389/fmed.2021.630660. eCollection 2021.
Portal vein thrombosis (PVT) is a rare and severe clinical phenotype of antiphospholipid syndrome (APS) with a poor prognosis. Anticoagulation therapy is efficient but is associated with potentially severe bleeding episodes, especially for those patients with thrombocytopenia. We conducted this case-control study to explore the clinical features and associated factors of PVT in APS patients, the re-canalization rate of the PVT after anticoagulation and investigate the beneficial effects of early initiation of anticoagulation in patients with APS associated PVT. We enrolled patients with APS associated PVT as the case group, and age-, and entry-time-matched APS patients without PVT (1:2) as the control group. We explored the associated factors of PVT in APS patients using multivariate logistic regression analysis. The re-canalization rate of the PVT after anticoagulation was analyzed using the survival analysis. A total of 34 patients (8 males and 26 females) with APS-PVT were enrolled, with a median follow-up time of 3 years (1.5, 7 years). Multivariate logistic regression analysis showed that thrombocytopenia (OR 6.4, 95%CI 1.561-26.218, = 0.01), hypersensitive c-reactive protein >3 mg/L (OR 4.57, 95%CI 1.426-14.666, = 0.011), anti β2GPI positive (OR 5, 95%CI 1.816-13.772, = 0.002) and aPL double-positive (OR 4.08, 95%CI 1.312-12.429, = 0.013) were independent associated factors for PVT in APS. Survival analysis revealed that effective anticoagulation could increase re-canalization rate significantly (log-rank = 0.001), with better prognosis (lower mortality rate, log-rank = 0.045). PVT could be the first presentation of APS with insidious onset and atypical clinical symptoms and easily be misdiagnosed. For patients with APS, double aPLs positive, thrombocytopenia, and inflammation could be the associated factors of PVT. Early diagnosis and anticoagulation treatment can bring thrombus re-canalization thereby significantly improving the prognosis.
门静脉血栓形成(PVT)是抗磷脂综合征(APS)一种罕见且严重的临床表型,预后较差。抗凝治疗有效,但与潜在的严重出血事件相关,尤其是对于那些血小板减少的患者。我们进行了这项病例对照研究,以探讨APS患者中PVT的临床特征和相关因素、抗凝治疗后PVT的再通率,并研究早期启动抗凝治疗对APS相关PVT患者的有益效果。我们将APS相关PVT患者纳入病例组,将年龄和入组时间匹配的无PVT的APS患者(1:2)作为对照组。我们使用多因素逻辑回归分析探讨APS患者中PVT的相关因素。使用生存分析对抗凝治疗后PVT的再通率进行分析。共纳入34例APS-PVT患者(8例男性和26例女性),中位随访时间为3年(1.5,7年)。多因素逻辑回归分析显示,血小板减少(OR 6.4,95%CI 1.561-26.218,P = 0.01)、超敏C反应蛋白>3 mg/L(OR 4.57,95%CI 1.426-14.666,P = 0.011)、抗β2GPI阳性(OR 5,95%CI 1.816-13.772,P = 0.002)和抗磷脂抗体(aPL)双阳性(OR 4.08,95%CI 1.312-12.429,P = 0.013)是APS中PVT的独立相关因素。生存分析显示,有效的抗凝治疗可显著提高再通率(对数秩检验P = 0.001),预后更好(死亡率更低,对数秩检验P = 0.045)。PVT可能是APS的首发表现,起病隐匿,临床症状不典型,容易误诊。对于APS患者,aPL双阳性、血小板减少和炎症可能是PVT的相关因素。早期诊断和抗凝治疗可使血栓再通,从而显著改善预后。